Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Fresenius SE & Co. KGaA

Investor Presentation • Aug 2, 2007

166_ip_2007-08-02_0a5a4cad-8cac-49bc-bf88-1d45b451c28c.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

Health Care Worldwide

Conference Call – Results H1 2007, August 2, 2007

Fresenius

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

Agenda

  • I. Business Update
  • -Fresenius Group
  • Fresenius Kabi
  • Fresenius ProServe
  • -Fresenius Biotech

II. Financials H1 and Q2 2007 / Outlook 2007

Fresenius Group: Accomplishments

  • Strong operating performance in all business segments
  • Encouraging Biotech clinical trial results
  • Conversion into a European Company (SE)
  • New management and reporting structure for HELIOS and VAMED
  • Increased earnings guidance

Fresenius Group: Excellent Financial Results

Fresenius Group: Strong Sales and EBIT Growth in all Business Segments

Fresenius Kabi: Sales H1 2007 – Fully in Line with Guidance

€
m		 H
1
2
0
0
7		 H
1
2
0
0
6		 O
i
r
g
a
n
c
G
h
t
r
o
w
S
T
l
l
t
o
a
a
e
s		 9
8
6		 9
3
7		 7
%
S
B
P
d
t
t
y
r
o
u
c
e
g
m
e
n
:
I
f
i
T
h
n
s
o
n
e
r
a
p
u
y		 5
2
9		 5
1
3		 4
%
C
l
i
i
l
N
i
i
t
t
n
c
a
u
r
o
n		 3
9
8		 3
6
5		 1
1
%
T
f
i
T
h
l
r
a
n
s
s
o
n
e
c
n
o
o
g
u
y		 5
9		 5
9		 1
%

Fresenius Kabi: Organic Sales Growth of 7 %

Fresenius Kabi: 130 bps EBIT Margin Improvement Compared to H1 2006

€
m		 H
1
2
0
0
7		 H
1
2
0
0
6		 C
h
a
n
g
e
E
B
I
T
E
B
I
T
i
m
a
r
g
n		 1
5
9
1
6.
1
%		 1
3
9
1
4
8
%		 1
4
%
E
B
I
T
b
R
i
y
e
g
o
n
:
E
r
o
p
e
ƒ
u
E
B
I
T
i
m
a
r
g
n		 1
4
5
2
1.
5
%		 1
2
4
1
9.
0
%		 1
7
%
I
i
l
t
t
n
e
r
n
a
o
n
a
ƒ
E
B
I
T
i
m
a
r
g
n		 5
0
1
6.
0
%		 4
6
1
6.
3
%		 9
%
C
d
C
R
&
D
t
t
o
r
p
o
r
a
e
a
n
o
r
p
o
r
a
e
ƒ		 3
6
-		 3
1
-		 1
6
%
-
N
i
t
e
n
c
o
m
e		 8
7		 6
0		 4
5
%

Fresenius Kabi: 2007 Financial Outlook Fully Confirmed

G
i
d
u
a
n
c
e
O
i
h
t
r
g
a
n
c
r
e
e
n
e
g
r
o
v
u
w		 6
8
%
–
E
B
I
T
i
m
a
r
g
n		 1
6
0
1
6
5
%
–

Fresenius ProServe: Accomplishments

Inauguration of the new maximum care hospital Berlin-Buch

Acquisition of a 255 bed hospital in Hamburg (sales 2006: ~ 26 €m)

Divestiture of Pharmatec completed end of June 2007

Fresenius ProServe: Sales Growth Fully in Line with Guidance

€
m		 H
1
2
0
0
7		 H
1
2
0
0
6		 C
h
a
n
g
e		 O
i
r
g
a
n
c
S
l
a
e
s		 1
0
6
9
,		 9
7
4		 1
0
%		 2
%
S
l
b
D
i
i
i
a
e
s
y
v
s
o
n
:
O
H
i
l
i
t
t
O
S
(
H
E
L
I
)
o
s
p
a
p
e
r
a
o
n
s		 8
9
0		 6
7
7		 1
6
%		 3
%
S
E
i
i
i
f
h
i
l
t
n
g
n
e
e
r
n
g
+
e
r
c
e
s
o
r
o
s
p
a
s
v
(
)
V
A
M
E
D
P
h
t
+
a
r
m
a
e
c		 1
9
7		 2
0
*
7		 1
4
%
-		 2
%
-
O
d
i
k
E
i
i
b
i
t
r
e
r
n
a
e
n
g
n
e
e
r
n
g
s
n
e
s
s
u		 1
0
6		 *
1
8
5		 4
3
%
-		 3
%
5
-
*
Inc
lu
d
ing
P
ha
lan
rm
ap

Fresenius ProServe: 60 bps EBIT Margin Improvement Compared to H1 2006

€
m		 H
1
2
0
0
7		 H
1
2
0
0
6		 G
h
t
r
o
w
E
B
I
T
E
B
I
T
i
m
a
r
g
n		 5
7
0
%
7.		 6
2
6
4
%		 2
1
%
E
B
I
T
b
D
i
i
i
y
v
s
o
n
:
H
i
l
i
t
t
ƒ
o
s
p
a
o
p
e
r
a
o
n
s
E
B
I
T
i
m
a
r
g
n		 6
8
6
%
7.		 5
6
3
%
7		 2
1
%
S
E
i
i
i
f
h
i
l
t
n
g
n
e
e
r
n
g
+
e
r
c
e
s
o
r
o
s
p
a
s
ƒ
v
E
B
I
T
i
m
a
r
g
n		 9
5.
0
%		 9
*
4
3
%		 -
C
t
t
o
r
p
o
r
a
e
c
o
s
s
ƒ		 2
-		 3
-		 3
3
%
*
Inc
lu
d
ing
P
ha
lan
rm
ap

Fresenius ProServe: 2007 Earnings Outlook Raised

Fresenius Biotech: Update

  • Secondary endpoints of phase II/III malignant ascites study confirm clear benefits from treatment with removab®
  • Partnering process for trifunctional antibody removab ® in North America and Japan ongoing
  • Submission of malignant ascites dossier to EMEA end of 2007 expected
  • 2007 EBIT outlook of ~ -50 €m confirmed

Fresenius Group: New Management and Reporting Structure for HELIOS and VAMED

  • Replace Fresenius ProServe by two new business segments as of 2008 – Fresenius HELIOS and Fresenius VAMED
  • Streamline corporate structure – reduce management layers
  • Increase transparency of financial reporting

Group Financials H1 2007 / Outlook 2007

Fresenius Group: Profit and Loss Statement

€
m		 Q
2
2
0
0
7		 H
1
2
0
0
7		 H
1
2
l
t
a
c
u
a
t
r
a
e
s		 0
0
Y
Y
7
o
t
t
c
o
n
s
a
n
t
r
a
e
s		 R
k
H
1
2
0
0
7
e
m
a
r
s
S
l
a
e
s		 2
8
2
5
,		 5
5
9
2
,		 1
0
%
+		 1
5
%
+		 %
i
h
7
t
o
r
g
a
n
c
g
r
o
w
E
B
I
T		 4
0
0		 7
8
0		 1
5
%
+		 2
0
%
+
I
l
t
t
t
n
e
r
e
s
r
e
s
u		 9
0
-		 1
8
5
-		 %
5
+		 1
%
-
T
a
x
e
s		 1
1
1
-		 2
1
4
-		 4
%
-		 9
%
-
N
i
t
e
n
c
o
m
e		 1
0
2		 1
9
5		 3
9
%
+		 4
4
%
+
S
E
P
(
f
)
(
€
p
r
e
s		 )
0
6
7		 1
2
7		 3
8
%
+		 4
2
%
+

Fresenius Group: Sales Growth Analysis H1 2007

Fresenius Group: Profit and Loss Statement

€
m		 Q
2
2
0
0
7		 H
1
2
0
0
7		 H
1
l
t
a
c
u
a
t
r
a
e
s		 2
0
0
Y
Y
7
o
t
t
c
o
n
s
a
n
t
r
a
e
s		 R
k
H
1
2
0
0
7
e
m
a
r
s
S
l
a
e
s		 2
8
2
5
,		 5
5
9
2
,		 1
0
%
+		 1
5
%
+		 %
i
h
7
t
o
r
g
a
n
c
g
r
o
w
E
B
I
T		 4
0
0		 7
8
0		 1
5
%
+		 2
0
%
+		 S
1
3.
9
%
E
B
I
T
i
t
r
o
n
g
m
a
r
g
n
I
l
t
t
t
n
e
r
e
s
r
e
s
u		 9
0
-		 1
8
5
-		 %
5
+		 1
%
-		 I
f
R
C
G
i
i
i
f
t
t
m
p
a
c
o
a
c
q
u
s
o
n
r
o
m
Q
2
0
6
T
a
x
e
s		 1
1
1
-		 2
1
4
-		 4
%
-		 9
%
-		 3
6
%
b
d
f
t
t
t
t
t
a
r
a
e
a
o
o
m
e
n
o
x
;
2
0
0
i
d
7
g
a
n
c
e
u
N
i
t
e
n
c
o
m
e		 1
0
2		 1
9
5		 3
9
%
+		 4
4
%
+		 H
1
0
6
i
l.
1
6
€
i
t
:
n
c
m
o
n
e-
m
e
e
x
p
e
n
s
e
s
S
E
P
(
f
)
(
€
p
r
e
s		 )
0
6
7		 1
2
7		 3
8
%
+		 4
2
%
+

Fresenius Group: Cash Flow

€
m		 Q
2
2
0
0
7		 H
1
2
0
0
7		 H
1
2
0
0
7
Y
Y
o		 R
k
H
1
2
0
0
7
e
m
a
r
s
C
f
h
l
a
s
o
w		 2
9
8		 8
2
5		 2
4
%
+		 S
i
h
t
t
r
o
n
g
e
a
r
n
n
g
s
g
r
o
w
C
h
i
W
k
i
i
a
n
g
e
n
o
r
n
g
c
a
p		 l
3
2
t
a
-		 2
9
-		 7
0
%
+
O
C
f
i
h
l
t
p
e
r
a
n
g
a
s
o
w		 2
6
6		 3
5
5		 4
8
%
+		 M
i
9.
9
%
a
r
g
n
:
C
(
)
t
a
p
e
n
e
x		 1
6
5
-		 2
9
7
-		 3
9
%
-		 I
i
i
h
t
t
t
n
e
s
n
g
n
o
g
r
o
v
w
C
f
h
l
a
s
o
w
(
f
)
b
i
i
i
d
d
i
i
d
d
t
e
o
r
e
a
c
q
s
o
n
s
a
n
e
n
s
u
v		 1
0
1		 2
6
5		 6
0
%
+
(
)
A
i
i
i
t
t
c
q
u
s
o
n
s
n
e		 9
9
-		 1
6
2
-		 9
5
%
+
D
i
i
d
d
e
n
s
v		 1
8
4
-		 1
8
8
-		 2
2
%
-
C
F
h
f
l
r
e
e
a
s
o
w
(
f
i
i
i
d
d
i
i
d
d
)
t
t
a
e
r
a
c
q
u
s
o
n
s
a
n
v
e
n
s		 1
8
2
-		 9
4
-		 9
7
%
+

Fresenius Group: Capex and Acquisitions – Investing into Growth

C
i
S
b
B
t
a
p
e
x
y
u
s
n
e
s
s
e
g
m
e
n		 A
i
i
i
b
R
i
t
c
q
u
s
o
n
s
y
e
g
o
n
s
H
1
2
0
0
7
€
m		 H
1
2
0
0
6
€
m		 C
h
a
n
g
e
%		 A
i
P
i
f
i
s
a-
a
c
c
2
%
7
E
r
o
p
e
u
C
F
i
M
d
i
l
r
e
s
e
n
s
e
c
a
a
u		 1
8
9
r
e		 1
4
1		 3
4		 4
5
%
F
i
K
b
i
r
e
s
e
n
s
a
u		 4
4		 3
7		 1
9		 R
W
o
F
i
P
S
r
e
s
e
n
u
s
r
o
e
r
v
e		 7
0		 4
1		 7
1		 6
%
C
t
o
r
p
o
r
a
e		 1 6 8
3
-		 N
h
A
i
t
o
r
m
e
r
c
a
2
2
%
G
r
o
u
p		 3
0
4		 2
2
5		 3
5		 T
l
2
2
1
€
t
o
a
m
:

Fresenius Group: Debt and Interest Ratios

Fresenius Group: Earnings Outlook 2007 Raised

Guidance

R
h
t
e
v
e
n
u
e
g
r
o
w		 8
1
0
%
t
t
t
a
c
o
n
s
a
n
c
u
r
r
e
n
c
y		 –
N
i
h
t
t
e
n
c
o
m
e
g
r
o
w
t
t
t
a
c
o
n
s
a
n
c
u
r
r
e
n
c
y		 R
i
d
a
s
e		 2
%
5
~
C
a
p
e
x		 €
6
0
0
7
0
0
m
–

Health Care Worldwide

Conference Call – Results 1st Half 2007, August 2, 2007

More from Fresenius SE & Co. KGaA

Declaration of Voting Results & Voting Rights Announcements 2025
Nov 17
Declaration of Voting Results & Voting Rights Announcements 2025
Nov 14
Report Publication Announcement 2025
Nov 6
Quarterly Report 2025
Nov 6
Interim / Quarterly Report 2025
Aug 6
Investor Presentation 2025
Aug 6
Declaration of Voting Results & Voting Rights Announcements 2025
Jul 4
Declaration of Voting Results & Voting Rights Announcements 2025
Jun 20
Governance Information 2025
May 23
Quarterly Report 2025
May 7
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.